competition is it better?
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane®) standard of care
as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis
Looks like the fat lady has not yet sung on AZD4320, page-15
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $40.90M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.5¢ | 9.7¢ | $22.92K | 232.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 236173 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 50800 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |